146 related articles for article (PubMed ID: 32231380)
1. Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker?
Thüring J; Kuhl CK; Barabasch A; Hitpass L; Bode M; Bünting N; Bruners P; Krämer NA
PLoS One; 2020; 15(3):e0230553. PubMed ID: 32231380
[TBL] [Abstract][Full Text] [Related]
2. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
3. Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases.
Torkzad MR; Riddell AM; Chau I; Cunningham D; Koh DM
AJR Am J Roentgenol; 2021 Mar; 216(3):669-676. PubMed ID: 33502225
[No Abstract] [Full Text] [Related]
4. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
[No Abstract] [Full Text] [Related]
6. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
8. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging.
d'Assignies G; Fina P; Bruno O; Vullierme MP; Tubach F; Paradis V; Sauvanet A; Ruszniewski P; Vilgrain V
Radiology; 2013 Aug; 268(2):390-9. PubMed ID: 23533288
[TBL] [Abstract][Full Text] [Related]
9. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
10. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
[TBL] [Abstract][Full Text] [Related]
11. Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
Öz A; Server S; Koyuncu Sökmen B; Namal E; İnan N; Balcı NC
Med Princ Pract; 2020; 29(5):429-435. PubMed ID: 31914438
[TBL] [Abstract][Full Text] [Related]
12. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
[TBL] [Abstract][Full Text] [Related]
13. MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study.
Milot L; Guindi M; Gallinger S; Moulton CA; Brock KK; Dawson LA; Haider MA
Radiology; 2010 Mar; 254(3):747-54. PubMed ID: 20123902
[TBL] [Abstract][Full Text] [Related]
14. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
[TBL] [Abstract][Full Text] [Related]
15. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
16. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.
Granata V; Catalano O; Fusco R; Tatangelo F; Rega D; Nasti G; Avallone A; Piccirillo M; Izzo F; Petrillo A
Abdom Imaging; 2015 Oct; 40(7):2364-71. PubMed ID: 26105523
[TBL] [Abstract][Full Text] [Related]
17. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
18. Focal hepatic lymphoma: magnetic resonance demonstration using current techniques including gadolinium enhancement.
Kelekis NL; Semelka RC; Siegelman ES; Ascher SM; Outwater EK; Woosley JT; Reinhold C; Mitchell DG
Magn Reson Imaging; 1997; 15(6):625-36. PubMed ID: 9285802
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted and T2-weighted MR imaging for colorectal liver metastases detection in a rat model at 7 T: a comparative study using histological examination as reference.
Wagner M; Maggiori L; Ronot M; Paradis V; Vilgrain V; Panis Y; Van Beers BE
Eur Radiol; 2013 Aug; 23(8):2156-64. PubMed ID: 23455763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
